Nigerian Govt Decries Pharma Production Levels

18 September 1994

The ability of Nigeria's pharmaceutical industry to increase production of drugs to meet an appreciable proportion of the nation's drug needs is causing the federal government a lot of concern, according to Health and Social Services Minister Dalhatu Sarki Tafida.

Speaking in the Nigerian capital Lagos at the 50th anniversary of May & Baker Nigeria, and the commissioning of a new liquid manufacturing plant, Mr Tafida said that inspite of government measures to encourage growth of the local pharmaceutical industry, the country still relies mostly on imported finished drugs and all inputs used in formulation and packaging to meet the industry's needs.

Foreign Exchange Problems He said the increase in the number of pharmaceutical industries within the last decade has not made any appreciable impact on drug availability, and added that "the amount of foreign exchange available to buy these has continued to diminish while the gap between demand and supply of medicines is widening by the day."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight